Comparing Bicycle Therapeutics (NASDAQ:BCYC) & Aurinia Pharmaceuticals (NASDAQ:AUPH)

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Bicycle Therapeutics (NASDAQ:BCYC) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.

Profitability

This table compares Aurinia Pharmaceuticals and Bicycle Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	97.68%	22.99%	17.99%
Bicycle Therapeutics	-169.75%	-26.02%	-22.30%

Institutional & Insider Ownership

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.2% of Bicycle Therapeutics shares are owned by institutional investors. 10.4% of Aurinia Pharmaceuticals shares are owned by insiders. Comparatively, 22.0% of Bicycle Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Aurinia Pharmaceuticals and Bicycle Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0	3	2	1	2.67
Bicycle Therapeutics	2	3	5	0	2.30

Aurinia Pharmaceuticals presently has a consensus target price of $17.33, indicating a potential upside of 6.93%. Bicycle Therapeutics has a consensus target price of $13.57, indicating a potential upside of 293.37%. Given Bicycle Therapeutics’ higher possible upside, analysts clearly believe Bicycle Therapeutics is more favorable than Aurinia Pharmaceuticals.

Valuation & Earnings

This table compares Aurinia Pharmaceuticals and Bicycle Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05 million	7.67	$287.20 million	$2.29	7.08
Bicycle Therapeutics	$72.86 million	3.31	-$218.96 million	($2.03)	-1.70

Aurinia Pharmaceuticals has higher revenue and earnings than Bicycle Therapeutics. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Aurinia Pharmaceuticals has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, Bicycle Therapeutics has a beta of 1.59, meaning that its share price is 59% more volatile than the S&P 500.

Summary

Aurinia Pharmaceuticals beats Bicycle Therapeutics on 9 of the 14 factors compared between the two stocks.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases. The Canadian company’s work has centered on therapies for conditions that can affect the kidneys and other organs. Its lead product, Lupkynis (voclosporin), is an oral medicine approved in the United States to treat adults with active lupus nephritis, a kidney complication of systemic lupus erythematosus. It is used in combination with background immunosuppressive therapy. Aurinia, formerly known as Isotechnika, developed voclosporin as a treatment for lupus nephritis.

About Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a focus on cancer. Founded in 2009, the company grew out of research at the University of Cambridge in the United Kingdom and has operations in Cambridge, UK, and Cambridge, Massachusetts. The company’s proprietary Bicycle platform creates small, constrained peptides that can bind to specific biological targets. Bicycle Therapeutics is using this technology to develop treatments that may be designed to reach targets that are difficult for conventional drugs to access.